Revolutionizing ELISA development: The transformative impact of automation on monoclonal antibody potency assays

Enzyme-linked immunosorbent assays (ELISA) are a fundamental technique for determining the potency of monoclonal antibodies (mAbs), yet the traditional ELISA development process is often time-consuming and labor-intensive. In this study, we explored how automation and miniaturization in a 384-well format can revolutionize ELISA development, significantly enhancing throughput and accuracy. By employing automated liquid dispensing technology, we streamlined the optimization of assay parameters, leading to faster and more reliable potency measurements. Our findings not only demonstrate the feasibility of this innovative approach but also highlight its potential to transform the landscape of analytical assays in biopharmaceutical development.